VCU Health to Become Third U.S. Site for VISABL-AFL

• VCU Health's Institutional Review Board has approved enrolment in Imricor's VISABL-AFL clinical trial
• VCU Health is the third U.S. site approved to join the trial
• Procedures are expected to commence in March 2026

Imricor Medical Systems, Inc. (ASX: IMR) has announced that the Institutional Review Board (IRB) of Virginia Commonwealth University Health (VCU Health) has approved VCU Health's enrolment in Imricor's VISABL-AFL clinical trial, supporting the U.S. FDA approval process for Imricor's ablation products. VCU Health is now the third U.S. site approved to join the trial. Next steps include final budgeting, installation, and training, all expected to be completed in February 2026. Procedures are expected to commence in March 2026. The Principal Investigator for VISABL-AFL at VCU Health is Dr. Ajay Pillai MD, who commented that Imricor's Northstar mapping system and Vision-MR mapping and ablation catheters represent a paradigm shift in cardiac ablation, with the potential to visualize arrhythmogenic substrate and the effects of ablation being extraordinarily impactful and meaningful for patient outcomes. Imricor's Chair and CEO, Steve Wedan, expressed excitement at having Dr. Pillai and the VCU team join the VISABL-AFL trial and looked forward to commencing procedures there in short order.